Complement activation during cardiopulmonary bypass. Comparison of bubble and membrane oxygenators.
A prospective randomized trial involving 91 patients undergoing cardiopulmonary bypass compared the effects of bubble oxygenators (with and without methylprednisolone sodium succinate) and membrane oxygenators on complement activation and transpulmonary sequestration of leukocytes. Patients were divided as follows: Group I, 30 patients, bubble oxygenator; Group II, 31 patients, bubble oxygenator and methylprednisolone sodium succinate (30 mg/kg); Group III, 30 patients, membrane oxygenator. In Group I, C3a increased from 323 +/- 171 ng/ml during cardiopulmonary bypass to 1,564 +/- 785 ng/ml at 25 minutes after bypass (p less than 0.0001). A significant decrease in C3a was found in Groups II and III compared to Group I (p less than 0.0001). C5a did not change significantly during cardiopulmonary bypass in any group. Reestablishment of pulmonary circulation at the end of bypass produced significant transpulmonary leukocyte sequestration in Group I; the median cell difference was 1,700/microliter. Transpulmonary sequestration was significantly (p less than 0.0001) less in Group II (median cell difference = 200/microliter) and in Group III (median cell difference = 400/microliter) than in Group I. We conclude that cardiopulmonary bypass with a bubble oxygenator alone initiates significantly (p less than 0.0001) more C3a activation and leukocyte sequestration than when methylprednisolone sodium succinate (30 mg/kg) is given 20 minutes before the start of cardiopulmonary bypass with a bubble oxygenator or when a silicone membrane oxygenator is used.
D000305:Adrenal Cortex Hormones / Q000494:pharmacology; D000328:Adult; D000368:Aged; D002315:Cardiopulmonary Bypass / Q000009:adverse effects; D002986:Clinical Trials as Topic; D003167:Complement Activation / Q000187:drug effects; D003176:Complement C3 / Q000378:metabolism; D015926:Complement C3a; D005260:Female; D006331:Heart Diseases / Q000276:immunology / Q000601:surgery; D006801:Humans; D007964:Leukocytosis / Q000209:etiology / Q000276:immunology; D008297:Male; D008875:Middle Aged; D010106:Oxygenators / Q000009:adverse effects; D010107:Oxygenators, Membrane / Q000009:adverse effects; D011446:Prospective Studies; D011897:Random Allocation; D013997:Time Factors
D000305:Adrenal Cortex Hormones; D003176:Complement C3; D015926:Complement C3a